Global Allergy Immunotherapy Revenue Is About 1100 Million USD In 2017
Thursday, 01 Nov, 2018
The primary therapeutic goals of allergy immunotherapy (AIT) include reducing symptoms, reducing symptomatic medication use, and improving allergyrelated quality of life. The evidence is strong that AIT achieves these goals and can alter the course of the disease, with benefits persisting in many patients for several years after treatment discontinuation.

In the last several years, global market of Allergy Immunotherapy developed rapidly, with an average growth rate of 10.7%. In 2017, global revenue of Allergy Immunotherapy is about 1100 million USD. Today, allergic diseases affect the lives of more than one billion people worldwide. With an epidemic rise over the last 60 years, prevalence is expected to reach up to four billion people by 2050. Globally, the market is characterized by growing prevalence, unmet patient needs and opportunities for tailored treatment.

The classification of Allergy Immunotherapy includes Subcutaneous Immunotherapy and Sublingual Immunotherapy. The proportion of Subcutaneous Immunotherapy in 2017 is about 55.1%, and the proportion of Sublingual Immunotherapy in 2016 is about 44.9%. 

Allergy Immunotherapy are application in Allergic Rhinitis, Allergic Asthma and Other. The most of Allergy Immunotherapy is used in Allergic Rhinitis, and the market share of that is about 45.3 % in 2017.

Europe is the largest consumption place, with a consumption market share nearly 68.5% in 2017, Allergy is the most common chronic disease in Europe. Up to 20% of patients with allergies struggle daily with the fear of a possible asthma attack, anaphylactic shock, or even death from an allergic reaction. Following Europe, North America is the second largest consumption place with the consumption market share of 19.2% in 2017. Allergy Immunotherapy market in Asia Pacific region is expected to exhibit the highest growth rate due to high incidence of allergy people in the developing Asian countries like China & India. 

Market competition is intense. ALK-Abello, Stallergenes Greer, Merck, Allergy Therapeutics, etc. are the leaders of the industry with the market share is about 76.6% in 2017.